Literature DB >> 18821613

High relapse rate seen at week 72 for patients treated with R1626 combination therapy.

Paul Pockros, David Nelson, Eliot Godofsky, Maribel Rodriguez-Torres, Gregory T Everson, Michael W Fried, Reem Ghalib, Stephen Harrison, Lisa Nyberg, Mitchell L Shiffman, Anna Chan, George Hill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18821613     DOI： 10.1002/hep.22593

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  7 in total

1.  New direct-acting antivirals in the development for hepatitis C virus infection.

Authors:  Paul J Pockros
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

Review 2.  New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.

Authors:  Jing Tong; You-wei Wang; Yuan-an Lu
Journal:  J Zhejiang Univ Sci B       Date:  2012-01       Impact factor: 3.066

Review 3.  [Viral hepatitis B und C].

Authors:  Markus Reiser
Journal:  Med Klin (Munich)       Date:  2009-05-16

4.  Antiviral therapy for hepatitis C virus: beyond the standard of care.

Authors:  Leen Delang; Lotte Coelmont; Johan Neyts
Journal:  Viruses       Date:  2010-03-29       Impact factor: 5.818

5.  A cell-based assay for RNA synthesis by the HCV polymerase reveals new insights on mechanism of polymerase inhibitors and modulation by NS5A.

Authors:  C T Ranjith-Kumar; Yahong Wen; Nielson Baxter; Kanchan Bhardwaj; C Cheng Kao
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

Review 6.  New treatments for chronic hepatitis C.

Authors:  Jae Young Jang; Raymond T Chung
Journal:  Korean J Hepatol       Date:  2010-09

Review 7.  The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.

Authors:  Mary K Yates; Katherine L Seley-Radtke
Journal:  Antiviral Res       Date:  2018-12-08       Impact factor: 10.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.